 |
Top 4 Pancreatic cancer treatment startups in USA
Updated: April 15, 2024 |
1
Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
2
Funding: $181.2M
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
3
Funding: $14.9M
ACT is developing implantable devices to infuse chemotherapy drugs directly into affected organs, targeting difficult-to-reach tumors while largely sparing surrounding tissues, organs and blood vessels.
ACT is developing implantable devices to infuse chemotherapy drugs directly into affected organs, targeting difficult-to-reach tumors while largely sparing surrounding tissues, organs and blood vessels.
4
Funding: $625K
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy. The startup’s lead candidate ACXT-3102, enables effective ligand binding to deliver targeted cytotoxic payloads in patients suffering from pancreatic adenocarcinoma. Accuronix also is developing MTDCs for other types of cancers such as breast or brain cancer.
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy. The startup’s lead candidate ACXT-3102, enables effective ligand binding to deliver targeted cytotoxic payloads in patients suffering from pancreatic adenocarcinoma. Accuronix also is developing MTDCs for other types of cancers such as breast or brain cancer.